Ebola vaccine human trial begins in the US

The Clinical Center Building, where the testing on humans with an experimental vaccine to prevent the Ebola virus has begun, at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, 02 September 2014 The National Institutes of Health will test the safety of the vaccine on 20 healthy adult volunteers

The first of several Ebola vaccine trials has begun in the US with researchers studying how human immune systems respond to it.

Twenty healthy adult volunteers are being tested at the National Institutes of Health (NIH) in Maryland.

The trial has been brought forward amid an outbreak of the disease in West Africa that has killed at least 1,500.

No volunteers will be infected with the Ebola virus but the vaccine has performed well in primate trials.

There is no cure for Ebola but a separate experimental drug, ZMapp, was 100% effective in studies on monkeys, according to researchers who published their data in Nature last week.

The treatment has not been officially studied in humans, but it was used on seven people infected with Ebola in West Africa, mostly health workers.

Two of them later died and it is unclear if the drug helped the others to recover. The fatality rate during this outbreak has been about 50%, according to the World Health Organization (WHO).

Ebola virus There is no cure for Ebola, and this outbreak has had a 50% fatality rate

At least 3,000 people have been infected with the virus. On Friday a fifth country, Senegal, had its first confirmed case.

WHO has warned it could get much worse and infect more than 20,000 people.

"There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection," said Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which helped develop the drug.

Researchers in Bethesda, Maryland, will be looking for any adverse reactions and how each volunteer's immune system responds to the vaccine.

NIH is also partnering internationally with the Wellcome Trust and others for a similar trial in the UK, the Gambia and Mali.

More on This Story

More US & Canada stories

RSS

Features & Analysis

Elsewhere on the BBC

  • FrogsBright...but deadly

    The vivid skin of the Amazon's golden poison arrow frog contains toxins strong enough to kill a human

Programmes

  • Islamic StateClick Watch

    Can the location of Islamic State militants be found with open source data?

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.